Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Lumen Meds vs Mint Med

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #328

Lumen Meds

Shoppers who want a domain-matched LegitScript certificate and a flat tirzepatide price, not a semaglutide quote.

Visit Lumen Meds
VS
Grade C · #334

Mint Med

Cost-first shoppers who want the simplicity of one flat price across both semaglutide and tirzepatide, in the 35 states it explicitly serves.

Visit Mint Med

The verdict

Winner · Lumen MedsGrade C vs C

Lumen Meds takes it, leading the Cost-Efficiency Index 56 to 55. Lumen Meds (Lumen Meds LLC, New Castle, DE) is a compounded GLP-1 telehealth platform with a domain-matched LegitScript certification (#47534109) and a real, flat tirzepatide price of $195.82/month including doctor visit, medication. Mint Med still earns a CCost-first shoppers who want the simplicity of one flat price across both semaglutide and tirzepatide, in the 35 states it explicitly serves.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Lumen Meds.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

52
45

Price Transparency

80
54

Nationwide Access

24
66

Formulation Options

53
40

Clinical Oversight

76
74

Contract Flexibility

55
61

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecLumen MedsMint Med
Cost-Efficiency Index56/10055/100
Semaglutide / moNot disclosedNot disclosed
Tirzepatide / mo$196/mo (all doses, plus a separate fee, compounded)Not disclosed
Semaglutide / yr (modeled)
Tirzepatide / yr (modeled)$2,352
CoverageCoverage not published36 states
Oral / sublingualNoNo
Brand-name accessCompounded onlyCompounded only
Rank here#328#334

Lumen Meds

56/100

Where the value is

  • Named legal entity with a real street address (Lumen Meds LLC, 128 Sunset Blvd #1214, New Castle, DE)
  • LegitScript verification seal specifically matches the lumenmeds.com domain, with a checkable certificate number (47534109) — unlike some peers whose badge verifies a different domain
  • Tirzepatide priced clearly and flatly at $195.82/month, same price at every dose, with no membership fee

The tradeoffs

  • Semaglutide's price is displayed on the site as literally '$0.00/month' with no explanation and no standard ongoing rate published anywhere checked — a real semaglutide price cannot be confirmed
  • States served are not published anywhere on the site
Visit Lumen Meds

Full Lumen Meds review →

Mint Med

55/100

Where the value is

  • Single, simple flat price ($159/mo) applies to any dose of either drug — no dose-escalation surcharge structure to parse
  • No membership fee ('NO memberships!') and cancellation requires only 48 business hours notice
  • Explicit immediate-refund commitment if a clinical reviewer finds the applicant ineligible

The tradeoffs

  • Payment is collected upfront, before a clinician has reviewed and approved the prescription — patients front the money before knowing they'll be approved
  • Only 35 states are served by name — notably absent are several populous states not on the published list, so most shoppers should check it before assuming eligibility
Visit Mint Med

Full Mint Med review →

Regulatory note: the FDA issued a warning letter to Glow Medispa, LLC dba Mint Med in June 2026. We still list and link to Mint Med; you should know the letter is on the public record before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons